Eli Lilly is determined to be a key player in a future non-opioid pain treatment market, and has in-licensed a novel oral compound from Belgium’s Confo Therapeutics, paying $40m upfront in a deal worth up to $590m.
Lilly Doubles Down On Novel Pain Drugs With Confo Therapeutics Deal
Adds To Three Non-Opioid Candidates In Pipeline
Belgium’s Confo Therapeutics gains its first big pharma partner in the field of non-opioid pain treatment, giving the big pharma will test its master protocol approach as it put its R&D muscle behind this major area of unmet need.
